Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

8233 ARTÍCULOS , VIENDO DEL 4336 AL 4350

Cognitive frailty: a potential target for secondary prevention of dementia

Panza F, Lozupone M, Solfrizzi V, Stallone R, Bellomo A, Greco A, Daniele A, Seripa D, Logroscino G.

Expert Opin Drug Metab Toxicol. 2017 Oct;13(10):1023-1027. doi: 10.1080/17425255.2017.1372424. Epub 2017 Sep 5.

Phosphodiesterase-4B as a Therapeutic Target for Cognitive Impairment and Obesity-Related Metabolic Diseases

Clapcote SJ.

Adv Neurobiol. 2017;17:103-131. doi: 10.1007/978-3-319-58811-7_5.

Effectiveness of omega-3 fatty acid supplementation in patients with Alzheimer disease: A systematic review and meta-analysis

Araya-Quintanilla F, Gutiérrez-Espinoza H, Sánchez-Montoya U, Muñoz-Yañez MJ, Baeza-Vergara A, Petersen-Yanjarí M, Fernández-Lecaros L.

Neurologia (Engl Ed). 2020 Mar;35(2):105-114. doi: 10.1016/j.nrl.2017.07.009. Epub 2017 Oct 4.

Rheumatoid arthritis and risk for Alzheimer's disease: a systematic review and meta-analysis and a Mendelian Randomization study

Policicchio S, Ahmad AN, Powell JF, Proitsi P.

Sci Rep. 2017 Oct 9;7(1):12861. doi: 10.1038/s41598-017-13168-8.

Association between Antihypertensive Drug Use and the Incidence of Cognitive Decline and Dementia: A Meta-Analysis of Prospective Cohort Studies

Xu G, Bai F, Lin X, Wang Q, Wu Q, Sun S, Jiang C, Liang Q, Gao B.

Biomed Res Int. 2017;2017:4368474. doi: 10.1155/2017/4368474. Epub 2017 Sep 28.

Resveratrol, pterostilbene, and dementia

Lange KW, Li S.

Biofactors. 2018 Jan;44(1):83-90. doi: 10.1002/biof.1396. Epub 2017 Nov 23.

Pharmacologic Interventions to Prevent Cognitive Decline, Mild Cognitive Impairment, and Clinical Alzheimer-Type Dementia: A Systematic Review

Fink HA, Jutkowitz E, McCarten JR, Hemmy LS, Butler M, Davila H, Ratner E, Calvert C, Barclay TR, Brasure M, Nelson VA, Kane RL.

Ann Intern Med. 2018 Jan 2;168(1):39-51. doi: 10.7326/M17-1529. Epub 2017 Dec 19.

Cerebrospinal Fluid Biomarkers for Alzheimer's Disease: A View of the Regulatory Science Qualification Landscape from the Coalition Against Major Diseases CSF Biomarker Team

Arnerić SP, Batrla-Utermann R, Beckett L, Bittner T, Blennow K, Carter L, Dean R, Engelborghs S, Genius J, Gordon MF, Hitchcock J, Kaplow J, Luthman J, Meibach R, Raunig D, Romero K, Samtani MN, Savage M, Shaw L, Stephenson D, Umek RM, Vanderstichele H, Willis B, Yule S.

J Alzheimers Dis. 2017;55(1):19-35. doi: 10.3233/JAD-160573.

Biomarkers for the Early Detection and Progression of Alzheimer's Disease

Counts SE, Ikonomovic MD, Mercado N, Vega IE, Mufson EJ.

Neurotherapeutics. 2017 Jan;14(1):35-53. doi: 10.1007/s13311-016-0481-z.

Blood Biomarkers for Alzheimer's Disease: Much Promise, Cautious Progress

Keshavan A, Heslegrave A, Zetterberg H, Schott JM.

Mol Diagn Ther. 2017 Feb;21(1):13-22. doi: 10.1007/s40291-016-0241-0.

Tau Imaging in Alzheimer's Disease Diagnosis and Clinical Trials

Brosch JR, Farlow MR, Risacher SL, Apostolova LG.

Neurotherapeutics. 2017 Jan;14(1):62-68. doi: 10.1007/s13311-016-0490-y.

Aberrant proteolytic processing and therapeutic strategies in Alzheimer disease

Tomita T.

Adv Biol Regul. 2017 May;64:33-38. doi: 10.1016/j.jbior.2017.01.001. Epub 2017 Jan 5.

Alzheimer's Disease and the Routine Clinical Use of CSF Biomarkers

Martorana A.

CNS Neurol Disord Drug Targets. 2017;16(4):407-413. doi: 10.2174/1871527316666170124164854.

YKL-40 as a Potential Biomarker and a Possible Target in Therapeutic Strategies of Alzheimer's Disease

Muszyński P, Groblewska M, Kulczyńska-Przybik A, Kułakowska A, Mroczko B.

Curr Neuropharmacol. 2017;15(6):906-917. doi: 10.2174/1570159X15666170208124324.

A second wind for the cholinergic system in Alzheimer's therapy

Douchamps V, Mathis C.

Behav Pharmacol. 2017 Apr;28(2 and 3-Spec Issue):112-123. doi: 10.1097/FBP.0000000000000300.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias